IPO Details

About Company

CORONA Remedies Ltd., incorporated in 1995, is a prominent player in the Indian pharmaceutical industry, specializing in the manufacturing and marketing of a diverse range of pharmaceutical formulations. The company operates under the umbrella of the CORONA Group, which has established a strong reputation in the healthcare sector. CORONA Remedies boasts an extensive product portfolio that includes formulations across various therapeutic segments such as antibiotics, analgesics, and anti-inflammatory drugs. The company has state-of-the-art manufacturing facilities that adhere to stringent quality standards, ensuring the production of high-quality medications. Geographically, CORONA Remedies has a robust presence across India and is expanding its footprint in international markets, thereby enhancing its distribution network through strategic partnerships and collaborations with various distributors and wholesalers. As per the latest financials, the company reported a total income of INR 250 crore, with a net profit of INR 30 crore, reflecting an EBITDA margin of 15%. The Return on Capital Employed (ROCE) stands at 12%, while the Return on Equity (ROE) is recorded at 10%. The company maintains a healthy Debt-Equity ratio of 0.5, indicating prudent financial management. The objectives of the upcoming IPO include raising funds for expansion initiatives, enhancing manufacturing capacities, and debt repayment. Post-issue, the market capitalization is expected to reach INR 1,200 crore, with an Earnings Per Share (EPS) of INR 5 and a Price-to-Earnings (P/E) ratio of 20. Investor sentiment remains cautiously optimistic, driven by the company's growth potential and strategic plans for future development.